These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30263038)

  • 1. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Nutr Metab (Lond); 2018; 15():63. PubMed ID: 30263038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
    Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
    Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Green cardamom plus low-calorie diet can decrease the expression of inflammatory genes among obese women with polycystic ovary syndrome: a double-blind randomized clinical trial.
    Cheshmeh S; Ghayyem M; Khamooshi F; Heidarzadeh-Esfahani N; Rahmani N; Hojati N; Mosaieby E; Moradi S; Pasdar Y
    Eat Weight Disord; 2022 Mar; 27(2):821-830. PubMed ID: 34057705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
    Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
    Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of green cardamom on serum SIRT1, glycemic indices and triglyceride levels in patients with type 2 diabetes mellitus: a randomized double-blind placebo controlled clinical trial.
    Aghasi M; Koohdani F; Qorbani M; Nasli-Esfahani E; Ghazi-Zahedi S; Khoshamal H; Keshavarz A; Sotoudeh G
    J Sci Food Agric; 2019 Jun; 99(8):3933-3940. PubMed ID: 30701554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardamom supplementation improves inflammatory and oxidative stress biomarkers in hyperlipidemic, overweight, and obese pre-diabetic women: a randomized double-blind clinical trial.
    Kazemi S; Yaghooblou F; Siassi F; Rahimi Foroushani A; Ghavipour M; Koohdani F; Sotoudeh G
    J Sci Food Agric; 2017 Dec; 97(15):5296-5301. PubMed ID: 28480505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.
    Hosseinpour-Arjmand S; Amirkhizi F; Ebrahimi-Mameghani M
    J Clin Pharm Ther; 2019 Apr; 44(2):258-267. PubMed ID: 30585337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Farsi F; Mohammadshahi M; Alavinejad P; Rezazadeh A; Zarei M; Engali KA
    J Am Coll Nutr; 2016; 35(4):346-53. PubMed ID: 26156412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
    Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
    Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial.
    Rezaei SMA; Mohammadi F; Eftekhari MH; Ejtehadi F; Ghaem H; Mohammadipoor N
    BMC Nutr; 2023 Nov; 9(1):138. PubMed ID: 38012749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the pomegranate extract in improving hepatokines and serum biomarkers of non-alcoholic fatty liver disease: A randomized double blind clinical trial.
    Jafarirad S; Goodarzi R; Mohammadtaghvaei N; Dastoorpoor M; Alavinejad P
    Diabetes Metab Syndr; 2023 Jan; 17(1):102693. PubMed ID: 36535123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of whole blood copper, zinc, calcium, magnesium, and iron with non-alcoholic fatty liver disease in overweight and obese children.
    Huang Z; Luo M; Dai W; Yao Z; Ouyang S; Xu N; Zhou H; Li X; Zhong Y; Luo J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 49(3):426-434. PubMed ID: 38970517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.
    Rafie R; Hosseini SA; Hajiani E; Saki Malehi A; Mard SA
    Clin Exp Gastroenterol; 2020; 13():35-45. PubMed ID: 32158249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial.
    Darabi Z; Darand M; Yari Z; Hedayati M; Faghihi A; Agah S; Hekmatdoost A
    BMC Res Notes; 2019 Feb; 12(1):89. PubMed ID: 30767788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.